|
|
Line 22: |
Line 22: |
| ==Differential diagnosis== | | ==Differential diagnosis== |
| Leigh's disease must be differentiated from other diseases that cause neurological manifestations in infants. | | Leigh's disease must be differentiated from other diseases that cause neurological manifestations in infants. |
| {|
| | Leigh's disease must be differentiated from birth asphyxia, kernicterus, encephalitis, thiamine deficiency, Wilson's disease, biotin-responsive basal ganglia disease. Birth asphyxia and hyperbilirubinemia can cause damage to thalamus and basal ganglia, which can cause lesions similar to leigh's disease. |
| |- style="background: #4479BA; color: #FFFFFF; text-align: center;"
| |
| ! rowspan="2" |Diseases
| |
| ! colspan="4" |Type of motor abnormality
| |
| ! rowspan="2" |Clinical findings
| |
| ! rowspan="2" |Laboratory findings and diagnostic tests
| |
| ! rowspan="2" |Radiographic findings
| |
| |- style="background: #4479BA; color: #FFFFFF; text-align: center;"
| |
| !Spasticity
| |
| !Hypotonia
| |
| !Ataxia
| |
| !Dystonia
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Leigh syndrome]]
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Progressive [[psychomotor]] regression
| |
| *[[Seizures]]
| |
| *External [[ophthalmoplegia]]
| |
| *[[Lactic acidosis]]
| |
| *[[Vomiting]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Increased [[lactate]] levels in [[blood]] and [[CSF]]
| |
| *Genetic testing
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *MRI: abnormal [[white matter]] signal in the [[putamen]], [[basal ganglia]], and [[brainstem]] on T2 images
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Niemann-Pick]] disease type C
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Progressive [[neurodegeneration]]
| |
| *[[Hepatosplenomegaly]]
| |
| *Systemic involvement of [[liver]], [[spleen]], or [[lung]] preceedes [[neurologic]] symptoms
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Abnormal [[liver]] function tests
| |
| *[[Fibroblast]] cell culture with filipin staining
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *MRI:
| |
| **[[Cerebral]] and [[cerebellar]] [[atrophy]]
| |
| **Thinning of the [[corpus callosum]]
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Infantile Refsum disease
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Abnormalities of the [[optic nerve]] and disc
| |
| *[[Retinitis pigmentosa]]
| |
| *[[Sensorineural]] hearing loss
| |
| *[[Hepatomegaly]] and [[cirrhosis]]
| |
| *[[Neurologic]] deterioration is slower than in [[Zellweger syndrome]] or ALD
| |
| | style="background: #F5F5F5; padding: 5px;" |Elevated plasma VLCFA levels
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adrenoleukodystrophy]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Cognitive]] and behavioral abnormalities
| |
| *[[Adrenal insufficiency]]
| |
| *[[Hyperpigmented]] skin
| |
| *[[Gonadal dysfunction]]
| |
| *[[Neurologic]] deterioration progresses at a variable rate
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated plasma VLCFA levels
| |
| *Molecular [[genetic testing]] for mutations in the ABCD1 gene
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zellweger syndrome]]
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Craniofacial]] dysmorphism
| |
| *[[Hepatomegaly]]
| |
| *Neonatal [[seizures]]
| |
| *Profound developmental delay
| |
| *[[MRI]] findings include [[cortical]] and [[white matter]] abnormalities
| |
| *[[Neurologic deterioration]] is rapid and infants rarely survive beyond six months of age
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated plasma VLCFA levels
| |
| *Elevated levels of [[phytanic acid]], pristanic acid, and pipecolic acid in plasma and [[fibroblasts]]
| |
| *Reduced plasmalogen in [[erythrocytes]]
| |
| *Molecular [[genetic]] testing for [[mutations]] in the PEX1 or PEX6 genes
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pyruvate dehydrogenase deficiency]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Lactic acidosis]]
| |
| *[[Seizures]]
| |
| *[[Intellectual disability]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated [[lactate]] and pyruvate levels in [[blood]] and CSF
| |
| *Abnormal PDH enzymatic activity in cultured fibroblasts
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Arginase deficiency]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Hyperammonemia]]
| |
| *[[Encephalopathy]]
| |
| *[[Respiratory alkalosis]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated [[ammonia]] level
| |
| *Elevated [[arginine]] level
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Holocarboxylase synthetase deficiency
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Ketoacidosis]]
| |
| *[[Dermatitis]]
| |
| *[[Alopecia]]
| |
| *[[Seizures]]
| |
| *[[Developmental delay]]
| |
| | style="background: #F5F5F5; padding: 5px;" |Elevated levels of:
| |
| | |
| *Beta-hydroxyisovalerate
| |
| *Beta-methylcrotonylglycine
| |
| *Beta-hydroxypropionate
| |
| *Methylcitrate
| |
| *Tiglylglycine
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Glutaric aciduria type 1
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Episodes of [[metabolic decompensation]] and [[encephalopathy]] often precipitated by [[infection]] and [[fever]]
| |
| *Rarely presents in the newborn period
| |
| *Microencephalic [[macrocephaly]]
| |
| *[[Seizures]] (approximately 20 percent)
| |
| *[[Cognitive function]] is preserved
| |
| | style="background: #F5F5F5; padding: 5px;" |Elevated levels of:
| |
| | |
| *[[glutaric acid]]
| |
| *3-hydroxyglutaric acid
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *MRI:
| |
| **[[Frontal]] and [[temporal]] [[atrophy]]
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ataxia telangiectasia]]
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Progressive [[cerebellar]] [[ataxia]]
| |
| *Abnormal eye movements
| |
| *[[Oculocutaneous]] [[telangiectasias]]
| |
| *Immune deficiency
| |
| *Increased risk of [[malignancy]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated serum alpha-fetoprotein level
| |
| *Low [[IgA]] and [[IgG]] levels
| |
| *[[Lymphopenia]]
| |
| *Genetic testing for [[mutation]] in the ATM gene
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pontocerebellar]] [[hypoplasias]]
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Progressive muscle [[atrophy]]
| |
| *[[Microcephaly]]
| |
| *[[Developmental delay]]
| |
| | style="background: #F5F5F5; padding: 5px;" |[[Genetic]] testing for PCH gene mutations
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *MRI :
| |
| **Small [[cerebellum]] and [[brainstem]] including the [[pons]]
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Metachromatic leukodystrophy]]
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Regression of motor skills
| |
| *[[Seizures]]
| |
| *[[Optic atrophy]]
| |
| *Reduced or absent [[deep tendon reflexes]]
| |
| *[[Intellectual disability]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Deficient arylsulfatase A enzyme activity in [[leukocytes]] or cultured skin fibroblasts
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pelizaeus-Merzbacher]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Nystagmus]]
| |
| *[[Cognitive impairment]]
| |
| *Onset in infancy
| |
| *Slowly progressive
| |
| *Language development may be normal
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Genetic]] testing for [[mutations]] in PLP1 gene
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *MRI:
| |
| **[[White matter]] abnormalities
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Angelman syndrome]]
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Profound [[intellectual disability]]
| |
| *Postnatal [[microcephaly]]
| |
| *Typical abnormal behaviors (paroxysmal laughter, easily excitable)
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Methylation studies and [[chromosome]] microarray to detect chromosome 15 anomalies and UBE3A mutations
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Rett syndrome]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Occurs almost exclusively in females
| |
| *Normal development during first six months followed by regression and loss of milestones
| |
| *Loss of speech capability
| |
| *Stereotypic hand movements
| |
| *[[Seizures]]
| |
| *[[Autistic]] features
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Clinical diagnosis
| |
| *[[Genetic]] testing for MECP2 mutations
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lesch-Nyhan syndrome]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Self-mutilating]] behavior
| |
| *[[Urinary]] stones due to [[hyperuricemia]]
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Elevated [[uric acid]] level
| |
| *Abnormal enzymatic activity of HPRT in cultured fibroblasts
| |
| *[[Genetic]] testing for HPRT gene [[mutations]]
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Miller-Dieker lissencephaly
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *[[Lissencephaly]]
| |
| *[[Microcephaly]]
| |
| *[[Dysmorphic]] features
| |
| *[[Seizures]]
| |
| *Failure to thrive
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Cytogenetic testing for 17p13.3 microdeletion
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Dopa-responsive [[dystonia]]
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | -
| |
| | style="background: #F5F5F5; padding: 5px;" | +
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Onset in early childhood
| |
| *Symptoms worsen with [[fatigue]] and exercise
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| *Positive response to a trial of [[levodopa]]
| |
| | style="background: #F5F5F5; padding: 5px; text-align: center;" | --
| |
| |}
| |
|
| |
|
| ==Diagnosis== | | ==Diagnosis== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Leigh's disease, a form of Leigh syndrome, also known as Subacute Necrotizing Encephalomyelopathy (SNEM), is a rare, inherited neurodegenerative disorder that mainly affects the central nervous system and becomes apparent during infancy, often after a viral illness. There is progressive loss of mental and movement abilities (psychomotor regression) and often leads to death within 2-3 years, usually due to respiratory failure.
Historical Perspective
Leigh's Syndrome was first described by Archibald Denis Leigh, a British neuropsychiatrist, in 1951. [1]
Pathophysiology
It is thought that manifestation of Leigh's syndrome is caused by brain lesion at different parts including brainstem, basal ganglia, cerebellum, and other regions of the brain. Brain lesions may be present in different forms such as demyelination, gliosis, spongiosis, necrosis and capillary proliferation. Due to demyelination, neurons in brain loses their ability to communicate with other neurons which hampers basic life functions, movements and balance. Lactic acidosis may be observed in some patients with pyruvate buildup, due to defective oxidative phosphorylation. [2]
Causes
Leigh's syndrome may be caused by mutations of any of 30 different genes, present in nuclear DNA. The most common cause of Leigh's syndrome is mutations in a gene called SURF1 (surfeit1) among nuclear DNA genes. Around 20 % of the cases are found to be due to mutation in mitochondrial DNA. Among mitochondrial DNA genes, mutations in MT-ATP6 gene, that codes for ATP synthase is most common cause known to cause the disease. [3]
Epidemiology and Demographics
The prevalence of Leigh's Syndrome is approximately 1 per 40,000 live births individuals worldwide.[4]
Differential diagnosis
Leigh's disease must be differentiated from other diseases that cause neurological manifestations in infants.
Leigh's disease must be differentiated from birth asphyxia, kernicterus, encephalitis, thiamine deficiency, Wilson's disease, biotin-responsive basal ganglia disease. Birth asphyxia and hyperbilirubinemia can cause damage to thalamus and basal ganglia, which can cause lesions similar to leigh's disease.
Diagnosis
The diagnosis of Leigh's syndrome is suggested based on the clinical findings, confirmed through laboratory and genetic testing.
Diagnostic study of Choice
Magnetic resonance imaging (MRI) of the brain may reveal abnormal areas in certain parts of the brain including basal ganglia, brain stem, and grey matter.
History and Symptoms
Symptoms began to appear from infancy that begins with vomiting, diarrhoea, and poor sucking that leads to failure to thrive. On progressive note, muscular system involved leading to hypotonia (decrease tone), dystonia (sustained spasm) and ataxia (loss of control over movements). Muscles that controls eye movement get affected leading to ophthalmoparesis and nystagmus (involuntary eye movement). Lungs and heart can be involved leading to hypertrophic cardiomyopathy and respiratory failure, most common cause of death. Peripheral neuropathy have been noted in some cases of Leigh's syndrome. Hypertrichosis can be seen in some patient due SURF1 nuclear gene mutation.
[2]
Physical Examinations
Common physical examination findings of Leigh's syndrome include dystonia, nystagmus, autonomic dysfunction (due to damage to basal ganglia and brain stem).
Laboratory Findings
Laboratory findings consistent with the diagnosis of Leigh's syndrome include high levels of acidic waste products in the blood (lactic acidosis) as well as elevated levels of pyruvate and alanine.
Treatment
There is no treatment for Leigh's syndrome; the mainstay of therapy is supportive care. Anti-epileptic drugs can be used to manage patient who present with epilepsy. In addition, coenzyme Q10, thiamine and biotin can be used to supplement deficiencies. [5]
References
Template:Diseases of the nervous system
Template:Mitochondrial diseases
de:Leigh-Syndrom
nl:Leigh syndroom
Template:WH
Template:WS